L19IL2

Phase 2Small molecule

PPhilogen S.p.A.

L19IL2 is one of 137 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Skin CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

MelanomaActive, not recruiting

Locally Advanced Basal Cell CarcinomaRecruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Skin CancerPhase 2

Active, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Locally Advanced Basal Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

21 2

Tecentriq

Roche

Phase 3

11 3

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 4

Libtayo

Regeneron

Phase 3

6 5

Imjudo

AstraZeneca

Phase 3

2 6

Tuoyi

SSun Yat-sen University

Phase 3

4 7

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Epacadostat

1 10

L19IL2

PPhilogen S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma

NCT06284590

Q4 2028

Phase 3Active, not recruiting

Neoadjuvant

NCT02938299

Phase 1Recruiting

Solid Tumors

NCT06640413

Q1 2031

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227350

Clinical

Trials by Indication[1]

Solid Tumors1 trial

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Recruiting·PPhilogen S.p.A.·Phase 1·NCT06640413·56 enrolled

Neoadjuvant1 trial

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Active, not recruiting·PPhilogen S.p.A.·Phase 3·NCT02938299·214 enrolled

Metastatic Melanoma1 trial

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Unknown status·PPhilogen S.p.A.·Phase 1/2·NCT02076646·96 enrolled

Skin Cancer1 trial

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Unknown status·PPhilogen S.p.A.·Phase 2·NCT04362722·40 enrolled

Melanoma1 trial

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06284590·162 enrolled

2 more indications

Advanced Solid Tumours1 trial

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Completed·PPhilogen S.p.A.·Phase 1/2·NCT01058538·33 enrolled

Locally Advanced Basal Cell Carcinoma1 trial

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227350·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for L19IL2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L19IL2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L19IL2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhilogen S.p.A.

L19IL2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2031

Trials by Indication[1]

Solid Tumors1 trial

Neoadjuvant1 trial

Metastatic Melanoma1 trial

Skin Cancer1 trial

Melanoma1 trial

Advanced Solid Tumours1 trial

Locally Advanced Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News